注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。11月13日，据CDE官网最新公示，鲁南贝特制药以仿制4类报产的瑞维那新吸入溶液上市申请已获受理。摩熵医药数据显示，原研获批不久，国内多家明星药企提交了上市申请。截图来源：CDE瑞维那新（又名雷芬那辛）作为Mylan公司研发的长效毒蕈碱拮抗剂，于...
Source Link注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。11月13日，据CDE官网最新公示，鲁南贝特制药以仿制4类报产的瑞维那新吸入溶液上市申请已获受理。摩熵医药数据显示，原研获批不久，国内多家明星药企提交了上市申请。截图来源：CDE瑞维那新（又名雷芬那辛）作为Mylan公司研发的长效毒蕈碱拮抗剂，于...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.